Updates

Campaign Launches Nationwide Effort to Highlight Voter Concerns Over Rising Prescription Drug Prices

Jul 11, 2016

“Voters across the country are calling for action by their elected officials to make sure patients and families don’t have to choose between filling a prescription and putting food on the table,” said CSRxP Executive Director John Rother. “The trend of rising drug prices needs to be addressed, and we expect voters will take that message – and a call for solutions – to candidates at all levels this fall.” Read More

Drug Companies Protecting Their Monopoly To Keep Prices High

Jul 11, 2016

Our new board game illustrates how pharmaceutical companies have a monopoly on the current pricing system and the different ways they keep prices high. Read More

Market-Based Solutions to Address Soaring Drug Prices

Jul 8, 2016

Join the Campaign for Sustainable Rx Pricing on Capitol Hill for a discussion about market-based policy solutions to curb rising drug prices. Read More

CSRxP Statement on the Costly New Abuse-Deterrent Drug Provision

Jul 8, 2016

"With this provision, policymakers are rewriting the rules to benefit pharmaceutical manufacturers for slightly tweaking their product and reintroducing it as a new 'innovation,’” CSRxP Executive Director John Rother said. Read More

CSRxP Statement on New Data Showing Best-Selling Drug Prices Rising at Twice the Rate of Inflation

Jun 30, 2016

"When the sticker price for 30 out of 39 of the most sold drugs goes up by more than double the rate of inflation, consumers are left holding the bag. These price increases year after year compound the problem and the whole scheme is unsustainable.” Read More

CSRxP Statement on AstraZeneca seeking “Orphan Drug” designation for widely-used cholesterol drug Crestor

Jun 30, 2016

“Abusing rules and regulations to keep competitors out of the market is common in the prescription drug industry, but AstraZeneca’s latest undertaking is especially egregious." Read More

CSRxP Statement on Medicare Trustees Report

Jun 22, 2016

"Prescription drug costs are rising much faster than other parts of Medicare and putting ever greater financial pressure on the program and on its beneficiaries. It’s no wonder that voters are making prescription drug prices a top issue in this election." Read More

CSRxP Announces Support for Bipartisan CREATES Act

Jun 20, 2016

The Campaign for Sustainable Rx Pricing (CSRxP) announced its endorsement of the Creating and Restoring Equal Access to Equivalent Samples (“CREATES”) Act, a bill introduced today in the Unites States Senate. Read More

John Rother Statement on MEDPAC Report

Jun 15, 2016

"This MEDPAC report confirms exactly what we have been saying: rising drug prices are putting a colossal burden on America’s health care system and now total nearly 20 percent of health care spending. Without market-based solutions like transparency, competition, and value, we can only expect the problem to get worse.” Read More

Statement on Senators’ Probe of Opioid Overdose Treatment Price Spikes

Jun 10, 2016

“The pharmaceutical industry’s habit of hiking prices on life-saving medications is appalling. Our campaign has been active in drawing attention to the price spikes on naloxone and we welcome this bipartisan effort to expose pharma’s price gouging tactics." Read More

American Gastroenterological Association Joins Campaign for Sustainable Rx Pricing

Jun 8, 2016

The American Gastroenterological Association announced today that it has joined the Campaign for Sustainable Rx Pricing, a broad-based campaign working to curb rising drug costs. AGA, which has 16,000 members involved in all aspects of gastroenterology around the globe, adds its voice to the hospitals, physicians, pharmacists, nurses, health plans, patients, and employers already promoting CSRxP’s solutions of transparency, competition, and value in the prescription drug market. Read More

Rising Prescription Drug Prices: Can We Keep Up?

May 19, 2016

We need to move toward market-based solutions to increase transparency, promote competition, and enhance value. For the millions of Americans living with chronic conditions - including allergies and arthritis, these solutions cannot come soon enough. Read More